Table 1 Correlations between AGBL2 expression and clinicopathological features (n = 126)
From: Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer
Variables | N | AGBL2- | AGBL2+ | P value |
|---|---|---|---|---|
Age | 0.062 | |||
<35 Y | 18 | 14 | 4 | |
>35 Y | 108 | 60 | 48 | |
Tumor size | 0.562 | |||
T1 | 24 | 16 | 8 | |
T2 | 83 | 46 | 37 | |
T3 | 19 | 12 | 7 | |
Clinical stage | 0.001 | |||
I | 15 | 14 | 1 | |
II | 57 | 45 | 12 | |
III | 54 | 15 | 39 | |
Tumor stage | 0.151 | |||
DCIS | 16 | 7 | 9 | |
IDC | 110 | 67 | 43 | |
Metastatic nodes | 0.006 | |||
Negative | 50 | 38 | 12 | |
Positive | 76 | 36 | 40 | |
Her2 status | 0.632 | |||
Positive | 21 | 9 | 12 | |
Negative | 105 | 47 | 58 |